Targeting JAK

    • FDA-approved JAK inhibitors
      • Ruxolitinib (trade names: Jakafi and Jakavi) against JAK1/2 for treatment of myelofibrosis, being investigated for treatment of other cancers such as lymphomas and pancreatic cancer
      • Tofacitinib (trade name: Xeljanz) against JAK1/3 (JAK2 to a lesser degree) for treatment of rheumatoid arthritis
    • JAK inhibitors in clinical trials
      • Baricitinib against JAK1/2 for treatment of rheumatoid arthritis, psoriasis, and autoinflammatory diseases
      • CYT387 against JAK2 for myeloproliferative disorders
      • Lestaurtinib against JAK2 for acute myelogenous leukemia (AML)
      • Pacritinib (SB1518) against JAK2 for relapsed lymphoma and advanced myeloid malignancies and chronic idiopathic myelofibrosis (CIMF)
    Other topics in Molecular Targets and Pathways